-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
January-February is a concentrated period for listed pharmaceutical companies to intensively disclose their full-year forecasts for 2021
.
Recently, several companies have released their annual performance reports
.
According to the author's arrangement, as of February 22, 25 companies including Sanyou Medical, Zhijiang Bio, and Bairen Medical have disclosed their 2021 transcripts.
Let's take a look at their situation! From the perspective of revenue, 4 of the 25 listed pharmaceutical and biological companies have a revenue of over 10 billion yuan, namely Kelun Pharmaceutical, Sinopharm Hyundai, Zhifei Bio, and WuXi AppTec
.
Among them, Zhifei Biology recorded a revenue of 30.
637 billion yuan in 2021, followed by WuXi PharmaTech, with an annual revenue of 22.
902 billion yuan; 4 companies with revenue in the range of 5 billion yuan to 10 billion yuan, including Wantai Bio, Pien Tze Huang, etc.
; in addition, there are 9 companies with a revenue of over 1 billion yuan
.
In terms of year-on-year revenue growth, except for Zhijiang Bio, Baike Bio, and Watson Pharmaceuticals, the remaining 22 pharmaceutical and biological companies will all show positive revenue growth in 2021
.
Among them, there are 2 companies with a year-on-year increase of more than 100% in revenue, namely Wantai Bio and Zhifei Bio
.
In addition, the revenue of Haier Bio and Sanyou Medical increased by more than 50% year-on-year
.
In the whole year of 2021, there are 22 pharmaceutical and biological enterprises with net profit exceeding 100 million yuan.
Among them, WuXi PharmaTech's revenue exceeds 5 billion yuan, and Zhifei Bio's revenue exceeds 10 billion yuan
.
Judging from the year-on-year growth rate of net profit, three companies whose net profit will double in 2021 include Haier Bio, Wantai Bio, and Zhifei Bio.
Among them, Zhifei Bio’s net profit has increased by more than 200% year-on-year
.
In addition, except for Sinopharm Hyundai, Huasen Pharmaceutical and other 8 companies with negative year-on-year net profit growth, the net profit of the remaining companies all showed positive year-on-year growth
.
In general, the overall performance of the 25 pharmaceutical and biological companies is relatively bright
.
So, what are the reasons for the growth or decline of the performance of these pharmaceutical and biological companies? To sum up, the reasons for the growth of the above-mentioned pharmaceutical companies are mainly related to the sales growth of related products, and the companies actively embracing the Internet of Things and other factors. .
For example, Zhifei Biology stated in the report that the main reason for the change in performance was that during the reporting period, the company continued to focus on business development goals, increased investment in research and development, and introduced new products.
The sales of independent products and agency products continued to increase steadily.
Important financial indicators such as main business income and net profit have increased significantly compared with the same period of the previous year; WuXi AppTec stated in the financial report that the company continues to build an "integrated, end-to-end" CRDMO (Contract Research, Development and Production Organization) ) business, strong demand for orders has driven accelerated sales growth in 2021
.
Haier Bio said that the main driving factors for the company's high revenue growth are the continuous deepening of the Internet of Things strategy, the continuous innovation and iteration of technology and product solutions, and the company's accelerated channel network expansion to expand its global market competitiveness.
Double high growth in business
.
The reasons for the decline in the company's performance are mainly related to the impact of the epidemic, centralized procurement policies and other factors
.
Ruzhijiang Biology pointed out in the performance report that the main reason for the decline in performance was the centralized procurement of testing reagents, which led to the decline in the gross profit of the company's corresponding products; Watson Pharmaceuticals stated that the main reason for the decline in the company's operating income was orlistat, a cooperative product with Zeen Biotech.
Capsule sales revenue dropped significantly
.
However, the company further disclosed that at the end of the reporting period, the company further reached an agreement with its partner company, Zhien Biological, to commercialize orlistat capsules with its own brand "Quchang".
smooth) the gradual implementation of the commercialization plan, the sales revenue of this variety will be boosted
.
This data is compiled by Pharmaceutical Network (Photo source: Pharmaceutical Network) Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
.
Recently, several companies have released their annual performance reports
.
According to the author's arrangement, as of February 22, 25 companies including Sanyou Medical, Zhijiang Bio, and Bairen Medical have disclosed their 2021 transcripts.
Let's take a look at their situation! From the perspective of revenue, 4 of the 25 listed pharmaceutical and biological companies have a revenue of over 10 billion yuan, namely Kelun Pharmaceutical, Sinopharm Hyundai, Zhifei Bio, and WuXi AppTec
.
Among them, Zhifei Biology recorded a revenue of 30.
637 billion yuan in 2021, followed by WuXi PharmaTech, with an annual revenue of 22.
902 billion yuan; 4 companies with revenue in the range of 5 billion yuan to 10 billion yuan, including Wantai Bio, Pien Tze Huang, etc.
; in addition, there are 9 companies with a revenue of over 1 billion yuan
.
In terms of year-on-year revenue growth, except for Zhijiang Bio, Baike Bio, and Watson Pharmaceuticals, the remaining 22 pharmaceutical and biological companies will all show positive revenue growth in 2021
.
Among them, there are 2 companies with a year-on-year increase of more than 100% in revenue, namely Wantai Bio and Zhifei Bio
.
In addition, the revenue of Haier Bio and Sanyou Medical increased by more than 50% year-on-year
.
In the whole year of 2021, there are 22 pharmaceutical and biological enterprises with net profit exceeding 100 million yuan.
Among them, WuXi PharmaTech's revenue exceeds 5 billion yuan, and Zhifei Bio's revenue exceeds 10 billion yuan
.
Judging from the year-on-year growth rate of net profit, three companies whose net profit will double in 2021 include Haier Bio, Wantai Bio, and Zhifei Bio.
Among them, Zhifei Bio’s net profit has increased by more than 200% year-on-year
.
In addition, except for Sinopharm Hyundai, Huasen Pharmaceutical and other 8 companies with negative year-on-year net profit growth, the net profit of the remaining companies all showed positive year-on-year growth
.
In general, the overall performance of the 25 pharmaceutical and biological companies is relatively bright
.
So, what are the reasons for the growth or decline of the performance of these pharmaceutical and biological companies? To sum up, the reasons for the growth of the above-mentioned pharmaceutical companies are mainly related to the sales growth of related products, and the companies actively embracing the Internet of Things and other factors. .
For example, Zhifei Biology stated in the report that the main reason for the change in performance was that during the reporting period, the company continued to focus on business development goals, increased investment in research and development, and introduced new products.
The sales of independent products and agency products continued to increase steadily.
Important financial indicators such as main business income and net profit have increased significantly compared with the same period of the previous year; WuXi AppTec stated in the financial report that the company continues to build an "integrated, end-to-end" CRDMO (Contract Research, Development and Production Organization) ) business, strong demand for orders has driven accelerated sales growth in 2021
.
Haier Bio said that the main driving factors for the company's high revenue growth are the continuous deepening of the Internet of Things strategy, the continuous innovation and iteration of technology and product solutions, and the company's accelerated channel network expansion to expand its global market competitiveness.
Double high growth in business
.
The reasons for the decline in the company's performance are mainly related to the impact of the epidemic, centralized procurement policies and other factors
.
Ruzhijiang Biology pointed out in the performance report that the main reason for the decline in performance was the centralized procurement of testing reagents, which led to the decline in the gross profit of the company's corresponding products; Watson Pharmaceuticals stated that the main reason for the decline in the company's operating income was orlistat, a cooperative product with Zeen Biotech.
Capsule sales revenue dropped significantly
.
However, the company further disclosed that at the end of the reporting period, the company further reached an agreement with its partner company, Zhien Biological, to commercialize orlistat capsules with its own brand "Quchang".
smooth) the gradual implementation of the commercialization plan, the sales revenue of this variety will be boosted
.
This data is compiled by Pharmaceutical Network (Photo source: Pharmaceutical Network) Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
